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Long-term outcomes of diabetic patients
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Vikram Paruchuri, MD, Robert S. Crawford, MD, Christopher J. Kwolek, MD,
Glenn M. LaMuraglia, MD, and Richard P. Cambria, MD, Boston, Mass
Objective: Diabetes mellitus (DM) has traditionally predicted poor outcomes after lower extremity revascularization for
peripheral vascular disease (PVD). This study assessed the influence of DM on long-term outcomes of percutaneous
transluminal angioplasty, with or without stenting (PTA/stent), in patients with PVD.
Methods: From January 2002 to December 2007, 920 patients underwent 1075 PTA/stent procedures. Patients were
stratified into DM and non-DM cohorts. Study end points included primary patency (PP), assisted patency (AP), limb
salvage, and survival and were evaluated using Kaplan-Meier and Cox regression analyses.
Results: There were 533 DM and 542 non-DM limbs. Median follow-up was 34 months. Overall, the 5-year actuarial PP
was 42% 2.4%, AP was 81% 2.0%, limb salvage was 89% 1.6%, and survival was 60% 2.4%. On univariate analysis,
DM vs non-DMwas associated with inferior 5-year PP (37% 3.4% vs 46% 3.3%; P .009), limb salvage (84% 2.6%
vs 93%  1.8%, P < .0001), and survival (52%  3.5% vs 68%  3.1%, P  .0001). AP did not differ between DM and
non-DM patients (P .18). In the entire cohort, DM (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.01-1.54;
P  .04), single-vessel peroneal runoff (HR, 1.54; 95% CI, 1.16-2.08; P  .003), and dialysis (HR, 1.59; 95% CI,
1.10-2.33; P  .02) were associated with decreased PP on multivariate analysis. The only variables on multivariate
analysis to predict limb loss and death were critical limb ischemia (HR, 9.09; 95% CI, 4.17-20.00; P< . 0001; HR, 2.99;
95% CI, 2.01-4.44; P < .0001, respectively) and dialysis (HR, 2.94; 95% CI, 1.39-5.00; P  .003; HR, 4.24; 95% CI
2.80-6.45; P < .0001, respectively).
Conclusions: DM is an independent predictor of decreased long-term primary patency after PTA/stent. Although
acceptable assisted patency rates can be achieved with close surveillance and reintervention, long-term limb salvage
remains inferior in diabetic patients compared with non-diabetic patients due to a more severe clinical presentation and
poor runoff. ( J Vasc Surg 2010;52:314-22.)Percutaneous transluminal angioplasty with or without
stenting (PTA/stent) of infrainguinal arterial occlusive dis-
ease can be accomplished with low perioperative morbidity
and mortality.1 Although surgical bypass grafting remains
the gold standard for infrainguinal revascularization, ac-
ceptable midterm secondary patency and limb salvage rates
have led many to recommend PTA/stent as first-line ther-
apy in patients with chronic lower extremity ischemia.2,3
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314Patients with diabetes mellitus (DM) have a twofold to
fivefold increased risk of developing chronic lower extrem-
ity ischemia than the general population,4 and there is a
general belief among vascular surgeons that these patients
suffer from inferior results after arterial reconstruction.
Several more recent studies have challenged this notion,
with 3- to 5-year patency rates of 60% to 70% and excellent
limb salvage in patients with suitable greater saphenous
vein conduit.5-7 However, the long-term results of PTA/
stent in diabetic patients with chronic lower extremity
ischemia remain unknown.
Previous studies with limited follow-up have shown
that patency rates of infrainguinal PTA/stent are decreased
in diabetic patients compared with non-diabetic pa-
tients,2,8,9 and DM has been found to be a significant
predictor of limb loss.1,8 The goal of this study was to
determine the effect of DM on the long-term patency, limb
salvage, and survival of patients undergoing PTA/stent for
infrainguinal arterial occlusive disease.
METHODS
The clinical protocol for this study was approved by the
Institutional Review Board of the Massachusetts General
Hospital.
Patients. The study included all patients with infrain-
guinal arterial occlusive disease who were treated with
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The decision to use PTA/stent as first-line therapy was
based on the clinical examination, anatomic evaluation, and
judgment of the attending physician involved. Patients
were stratified into two cohorts based on the presence or
absence of DM, regardless of the adequacy of medical
control of the disease.
The diagnosis of DMwas determined from the hospital
records and confirmed by the current use of oral hypogly-
cemic agents or insulin. Renal insufficiency was defined as
serum creatinine level of 1.5 mg/dL, and patients were
considered to have a history of coronary artery disease even
if they had previously been revascularized with coronary
artery angioplasty or bypass grafting. Hypertension and
congestive heart failure were determined from the medical
records and confirmed by the use of appropriate medica-
tions. Individual limbs were counted separately so that
patients undergoing staged, bilateral procedures were re-
corded and evaluated as two entries.
Exclusion criteria included aortoiliac endovascular re-
construction, atherectomy, cryoplasty, mechanical throm-
bectomy, extended thrombolysis or other adjunctive en-
doluminal procedures, interventions for failing bypasses,
patients who presented with acute, critical limb ischemia
requiring emergent revascularization, or a functionally un-
salvageable limb.
Demographic, preoperative, perioperative, and postop-
erative data, including clinical presentation according to
Rutherford classification,10 lesion anatomy according to
the TransAtlantic Inter Society Consensus (TASC) I and II
femoropopliteal and tibial systems,11,12 and follow-up ankle-
brachial indices (ABI) or pulse volume recordings (PVR),
or both, were collected for each patient.
A multilevel intervention was defined as a femoropop-
liteal intervention in conjunction with a tibial intervention.
A multivessel intervention was defined as a PTA/stent in
more than one named vessel.
Technique. All infrainguinal interventions were per-
formed in our fixed-imaging operating room suite or car-
diac catheterization laboratory by a team of vascular sur-
geons, interventional cardiologists, and vascular medicine
interventionalists who satisfied the Massachusetts General
Hospital Vascular Center credentialing and the Society for
Vascular Surgery (SVS) criteria for performance of endo-
vascular procedures.
Patients with preoperative renal insufficiency were rou-
tinely given oralN-acetylcysteine before interventions, and
patients with severe azotemia were hydrated before and
after the procedure with sodium bicarbonate solution. Se-
lective angiography was performed under local anesthesia
and systemic heparin with a target activated clotting time of
200 to 250 seconds.
Access was typically obtained through a contralateral
femoral approach, but also through ipsilateral femoral or
left brachial approaches in select patients. No popliteal
punctures were used for vascular access. Lesions were
crossed endoluminally or subintimally with hydrophilic
(0.014-, 0.018-, 0.035-inch) or platinum-tipped (0.014-,0.018-inch) guidewires, and angiography was performed
to confirm distal endoluminal location. The decision to
intervene and the method of treatment were determined by
the attending operator.
Balloon angioplasty was performed with an appropri-
ately sized balloon that was chosen to match the nondis-
eased artery adjacent to the lesion. Selective stenting was
performed at the discretion of the operator for residual
stenosis 30%, flow-limiting dissection, intimal flap, or
acute occlusion. Balloon inflation pressures ranged from 4
to 12 atm and were held for at least 60 seconds. Comple-
tion angiography was performed to assess the technical
result. Sheaths were removed under manual compression,
and closure devices were rarely used.
Lesion characteristics were determined by an examina-
tion of the procedure notes and individual images were
reviewed when necessary. Lower extremity disease was
categorized under TASC I and II femoropopliteal and
tibial systems.11,12 Disease was also categorized by inter-
vention location and patency of the distal runoff vessels. A
distal runoff vessel was considered patent in the absence of
an occlusion from its origin to the ankle.
After the procedure, unless contraindicated, all patients
were given a 300-mg loading dose of clopidogrel and
maintained on 75 mg/d for 6 to 12 weeks. On the day of
the procedure, all patients who were not currently taking
aspirin received 325 mg, which was continued indefinitely.
Postprocedural follow-up. Patients were routinely
evaluated at 6 weeks as outpatients with clinical examination
and lower extremity noninvasive studies, which included ABI
or PVR, or both, and at 3 to 6 month intervals thereafter.
Patients with noncompressible vessels were most commonly
monitored with PVR. Patency was determined according to
the Rutherford guidelines,10 and patients who were found to
have a loss of distal pulses, return of symptoms, or change in
ABI/PVR were imaged further with angiography when clin-
ically indicated. Follow-up also involved a review of all outpa-
tient clinic visits and hospital admissions documented in our
system-wide electronic medical record.
Definitions and end points. A failure of primary
patency (PP) included a return of symptoms in the face
of worsening ABI and dampened PVR due to recurrent
disease. Assisted patency (AP) was achieved through
secondary endovascular intervention regardless of
whether the recurrent lesion was a stenosis, occlusion, or
a new lesion in the same anatomic segment. Patients
requiring surgical bypass were not included in the AP
calculations. Limb salvage calculations included all major
amputations (below and above knee) but did not include
minor amputations (digit, transmetatarsal). Survival data
were obtained from medical records and the Social Se-
curity Database.
Statistical analysis. Patient demographic and risk fac-
tor data associated with patency and comparisons be-
tween the two cohorts were performed using 2 or the t
test, as appropriate. Actuarial patency and survival anal-
ysis was performed using Kaplan-Meier life tables with
Mantel-Cox log-rank univariate analysis to identify dif-
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confidence intervals (CI) were determined using a mul-
tivariate Cox proportional hazards model for data with
variable follow-up. All variables with P  .10 on univar-
iate Kaplan-Meier analysis were included in multivariate
Cox regression analysis, and all values of P  .05 were
Table. Demographics, clinical, and anatomic data
Variable Overall
Limbs, No. 1075
Preoperative comorbidities
Age, yearsa 71.15  0.34
History of tobacco use 774
Male gender 691
Hypertension 996
Congestive heart failure 185
Coronary artery disease 661
Diabetes mellitus 533
Insulin-dependent 255
Non-insulin-dependent 278
Chronic renal insufficiency 278
Dialysis 78
Hypercholesterolemia 835
Preoperative medications
Clopidogrel 879
-Blocker 602
Statin 768
Warfarin 245
Indications
Claudicationb 627
Critical limb ischemiac 448
Runoff
Single-vessel 331
Single-vessel peroneal 110
Lesion characteristics
Stenosis only 596
Occlusion only 306
Sum lesion lengths, cma 6.91  0.20
Femoropopliteal TASC I
TASC IA 124
TASC IB 271
TASC IC 356
TASC ID 28
Femoropopliteal TASC II
TASC IIA 56
TASC IIB 574
TASC IIC 88
TASC IID 28
Tibial TASC
TASC A 0
TASC B 0
TASC C 148
TASC D 100
Intervention
Isolated femoropopliteal 778
Isolated tibial 89
Multilevel 208
Multivessel 516
Stent 361
DM, Diabetes mellitus; TASC, TransAtlantic InterSociety Consensus.
aData presented as mean  standard error of the mean.
bRutherford class 1-3.
cRutherford class 4-6.considered significant.RESULTS
Infrainguinal endovascular intervention was performed
in 1075 limbs of 920 patients. There were 533DM (49.6%)
and 542 non-DM (50.4%) limbs. Significant clinical, de-
mographic, and anatomic features are summarized in the
MNo. (%) Non-DM No. (%) P value
533 542
0.41  0.47 71.88  0.48 .03
377 (71) 397 (73) .23
368 (69) 323 (60) .001
504 (95) 492 (91) .07
114 (21) 71 (13) .0006
368 (69) 293 (54) .0001
255 (48) ... .0001
278 (52) ...
175 (33) 103 (19) .0001
56 (11) 22 (4) .0001
427 (80) 408 (75) .15
428 (80) 451 (83) .10
308 (58) 294 (54) .12
391 (73) 377 (70) .47
128 (24) 117 (22) .34
245 (46) 382 (70) .0001
288 (54) 160 (30) .0001
205 (38) 126 (23) .0001
78 (17) 32 (6) .0001
292 (55) 304 (56) .67
145 (27) 161 (30) .36
6.87  0.26 6.95  0.30 .84
.46
57 (11) 67 (12) .76
137 (26) 134 (25) .18
163 (31) 193 (36) .46
11 (2) 17 (3) .40
.45
30 (6) 26 (5) .35
270 (51) 304 (56) .94
44 (8) 44 (8) .56
11 (2) 17 (3) .40
.41
0 0 —
0 0 —
95 (18) 53 (10) .0001
59 (11) 41 (8) .0001
350 (66) 428 (79) .0001
58 (11) 31 (6) .002
125 (23) 83 (15) .0007
271 (51) 245 (45) .06
160 (30) 201 (37) .01D
7Table. The diabetic patients were more frequently younger
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failure, coronary artery disease, chronic renal insufficiency, and
need for dialysis. The diabetic patients were more likely to
present with critical limb ischemia and single-vessel runoff and
were also more likely to have tibial TASC C and D lesions,
undergo tibial and multilevel intervention, and less likely to
have stent placement.
Median follow-up in the entire cohort was 34 months
(mean, 35 months). The PP at 1, 3, and 5 years was 72% 
1.5%, 54% 1.8%, and 42% 2.4%, respectively. On univar-
iate analysis, the 5-year PP of DM limbs was less than that of
non-DM limbs (37%3.4% vs 46%3.3%,P .009; Fig 1).
Other variables associated with poor PP included dialysis,
critical limb ischemia, single-vessel runoff, and single-vessel
peroneal runoff. Isolated femoropopliteal intervention was
associated with increased PP (Appendix Table I, online only).
OnCox proportional hazards multivariate analysis, DM (HR,
1.25; 95% CI, 1.01-1.54; P  .04), dialysis (HR, 1.59; 95%
CI, 1.10-2.33; P  .02), and single-vessel peroneal runoff
(HR, 1.54; 95% CI, 1.16-2.08; P .003) were independent
predictors of decreased PP. A Cox proportional hazards mul-
tivariate analysis of the DM cohort alone showed only critical
limb ischemia was an independent predictor of decreased PP
(HR, 1.52; 95% CI, 1.16-2.00; P .002; Appendix Table V,
online only).
There were 427 failures of the initial PTA/stent; of these,
198 patients were observed, 175 underwent a second PTA/
stent procedure, 30 underwent bypass, and 24 underwent
immediate amputation. Of the 175 patients who underwent a
second PTA/stent, 36 patients ultimately underwent surgical
revascularization.
In the entire cohort, AP at 1, 3, and 5 years was 97% 
0.6%, 88% 1.3%, and 81% 2.0%, respectively. There was
Fig 1. Kaplan-Meier curves show the primary patenc
undergoing percutaneous transluminal angioplasty.no difference in 5-year AP between DM and non-DM limbs(79%  3.1 vs 84%  2.6%, P  .18; Fig 2). On univariate
analysis, single-vessel runoff and femoropopliteal TASC II A
vs B, C, and D were associated with decreased AP (Appendix
Tables II and VI, online only). Cox proportional hazards
multivariate analysis identified single-vessel runoff (HR, 1.67;
95% CI, 1.08-2.56; P .02) as the only independent predic-
tor of decreased AP.
Limb salvage at 1, 3, and 5 years in the entire cohort was
95% 0.7%, 93% 0.9%, and 89% 1.6%, respectively. On
univariate analysis, DM limbs had decreased 5-year limb sal-
vage rates comparedwithnon-DMlimbs (84%2.6%vs93%
1.8%, P  .0001; Fig 3). Other variables associated with
limb loss included congestive heart failure, chronic renal in-
sufficiency, dialysis, critical limb ischemia, and single-vessel
runoff (Appendix Table III, online only). A history of tobacco
use, femoropopliteal intervention, and stent placement were
associated with improved limb-salvage on univariate analysis.
Independent predictors of limb loss on Cox proportional
hazards multivariate analysis included dialysis (HR, 2.94; 95%
CI, 1.39-5.00; P  .003), critical limb ischemia (HR, 9.09;
95% CI, 4.17-20.00; P  .0001), and single-vessel runoff
(HR, 1.45; 95%CI, 1.05-1.96; P .02). ACox proportional
hazards multivariate analysis of the DM cohort showed inde-
pendent predictors of limb loss were critical limb ischemia
(HR, 5.00; 95%CI, 2.04-12.50, P .0003) and single-vessel
runoff (HR, 1.61; 95% CI, 1.10-2.38; P  .02; Appendix
Table VII, online only).
Limb salvage was then stratified according to clinical
presentation with claudication or critical limb ischemia. There
was no statistically significant difference between DM and
non-DM patients in the 5-year limb salvage of patients pre-
sentingwith critical limb ischemia (72% 4.8%DMvs 79%
5.6% non-DM, P .15). Six DM patients and one non-DM
diabetic (DM) and non-diabetic (non-DM) patientsy ofpatient who originally presented with claudication (Ruther-
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0.3% non-DM, P  .02). Owing to the small number of
patients in these groups, statistical analysis could not be
performed. All patients were women, had single-vessel
runoff, and underwent isolated PTA/stent of the super-
ficial femoropopliteal arterial segment. All patients clin-
ically progressed to critical limb ischemia within 1 year.
Five patients underwent a repeat PTA/stent as a second-
ary procedure, and two were treated with infrainguinal
vein bypass. Mean time to amputation in this group was
30.7 months after the initial intervention.
In the entire cohort, survival at 1, 3, and 5 years was
Fig 2. Kaplan-Meier curves show the assisted patenc
undergoing percutaneous transluminal angioplasty.
Fig 3. Kaplan-Meier curves show limb salvage of diab
percutaneous transluminal angioplasty.86%  1.2%, 73%  1.6%, 60%  2.4%, respectively. Onunivariate analysis, the DM cohort had decreased 5-year
survival of 52% 3.5 compared with 68% 3.1% for the
non-DM cohort (P  .0001; Fig 4). Other variables
associated with poor long-term survival after PTA/stent
included increasing age, congestive heart failure, coro-
nary artery disease, chronic renal insufficiency, dialysis,
critical limb ischemia, single-vessel runoff, femoropopli-
teal TASC II A vs B, C, and D lesions, and amputation
(Appendix Table IV, online only). Statin use, isolated
femoropopliteal, multivessel, and multilevel interven-
tions had a positive effect on survival.
Independent predictors of poor long-term survival by
diabetic (DM) and non-diabetic (non-DM) patients
DM) and non-diabetic (non-DM) patients undergoingy ofetic (Cox proportional hazards multivariate analysis were in-
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coronary artery disease (HR, 1.39; 95% CI, 1.05-1.82; P
.02), chronic renal insufficiency (HR, 1.57; 95% CI, 1.17-
2.10; P  .003), congestive heart failure (HR, 1.75; 95%
CI, 1.32-2.33; P  .0001), critical limb ischemia (HR,
2.64; 95% CI, 1.98-3.51; P  .0001), and dialysis (HR,
2.71; 95% CI, 1.82-4.03; P  .0001). A Cox proportional
hazards multivariate analysis of the DM cohort alone found
independent predictors of poor long-term survival included
increasing age (HR, 1.04; 95% CI, 1.02-1.05; P .0001),
congestive heart failure (HR, 1.99; 95% CI, 1.41-2.79; P
.0001), critical limb ischemia (HR, 2.99; 95% CI, 2.01-
4.44; P  .0001), and dialysis (HR, 4.24; 95% CI, 2.80-
6.45; P  .0001; Appendix Table VIII, online only).
DISCUSSION
The incidence of DM continues to rise worldwide, and
despite advances in medical management, disease-related
sequelae continue to contribute to DM-related hospital
admissions.4 The Centers for Disease Control and Preven-
tion (CDC) trends and statistics on DM reports that in
2003, there were 873,000 hospital discharges with an
arterial-related lower extremity condition in diabetic pa-
tients, an almost threefold increase from 1980.13 In addi-
tion, DM has long been considered a risk factor for poor
outcomes (graft failure and amputation) after infrainguinal
revascularization despite an aggressive approach towards
risk factor control and surveillance. However, limb salvage
and survival rates can be improved with restoration of
in-line blood flow to the foot regardless of the method of
revascularization.14
The literature regarding the effect of DM on the out-
comes of PTA/stent remains inconsistent, likely secondary
to varied patient populations and limited follow-up. Giles
Fig 4. Kaplan-Meier curves show survival of diabeti
percutaneous transluminal angioplasty.et al15 reported that DMwas not an independent predictorof primary failure in 176 PTA/stent performed for critical
limb ischemia, and DeRubertis et al9 had similar findings
on a multivariate analysis of 385 patients treated with
PTA/stent. These series both had limited follow-up that
averaged 12 months. Indeed, in a previous report we
detailed the results of 238 femoropopliteal PTA/stent with
an average follow-up of 24 months and found that DMwas
not an independent predictor of primary failure.1 In the
current series, with longer follow-up, DM was an indepen-
dent predictor of failure of PP such that it is possible that
the negative results seen in previous reports were secondary
to limited surveillance intervals.
One of the obstacles preventing successful revascular-
ization of chronic lower extremity ischemia in diabetic
patients is the anatomic distribution of disease, which is
commonly a distal, tibial pattern with sparing of pedal
vessels.16 The higher prevalence of tibial disease inDMmay
contribute to early failure: recent studies have reported
1-year PP of 50% after tibial PTA/stent.15
It is common for diabetic patients to have multilevel
disease resulting in a higher incidence of critical limb isch-
emia than their nondiabetic counterparts. Indeed, the cur-
rent study found a significantly higher incidence of critical
limb ischemia in the DM cohort at presentation (54% vs
30%, P  .0001). DeRubertis et al9 reported a similar
distribution of critical limb ischemia between their diabetic
and nondiabetic populations (52.5% vs 36.2%, P  .004),
although when DM failed to remain a significant predictor
of failure of PP on multivariate analysis they attributed this
to the severity of clinical presentation. Bakken et al8 re-
ported a comparable penchant for critical limb ischemia in
their diabetic population, and again, DM was not a signif-
icant predictor of failure of PP, although that study only
examined superficial femoral artery interventions.8 These
) and non-diabetic (non-DM) patients undergoingc (DMtwo studies appear to support the notion that disease
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PTA/stent and would lead one to conclude that given a
similar Rutherford classification and runoff, there should be
no difference in outcomes between diabetic and nondia-
betic patients.
Although diabetic patients were more likely to present
with critical limb ischemia, the current study found that
DM was a predictor of poor PP on multivariate analysis.
This suggests that DM itself influences PP failure, indepen-
dent of the severity of clinical presentation. Because our
study had longer follow-up and an increased number of
tibial interventions than did the DeRubertis and Bakken
studies, it is likely that the inclusion of tibial interventions in
a patient population with a predilection for tibial disease, as
well as the increased number of patients with long term
follow-up, account for the fact that DM was an indepen-
dent predictor of poor PP.
Poor PP was also associated with single-vessel peroneal
artery runoff. This result contrasts with studies from the
bypass literature that examined the suitability of the pero-
neal artery as an outflow vessel for lower extremity bypass
and showed equivalent outcomes compared with other
tibial arteries.17,18 Previous studies from our institution
and others have identified impaired runoff as a predictor of
poor PP after PTA/stent.19-21 Others have argued that
poor runoff is a marker for increased disease severity and
not an independent predictor of poor PP in diabetic pa-
tients.9 Data from this study would suggest otherwise,
because there were significantly more diabetic than nondi-
abetic patients with single-vessel and single-vessel peroneal
artery runoff.
Dosluoglu et al,22 in the only study to examine the
effect of peroneal artery runoff on the outcomes of endo-
vascular intervention, found a 12-month PP of 73% in
patients with single-vessel peroneal artery runoff compared
with 77% in patients with non-single-vessel peroneal artery
runoff. Although this difference was not significant, the PP
survival curves diverged beyond 12 months such that
longer follow-up might have shown a statistical difference.
The use of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) in patients with cardiovascular
disease has a beneficial effect not only on the cholesterol
profile but also on morbidity and mortality.23-25 Corriere
et al26 found decreased restenosis rates after renal artery
angioplasty and stenting in patients who took statins pre-
operatively. However, no studies to date that have assessed
peripheral angioplasty have found a significant effect of
statins on infrainguinal endovascular outcomes. In the cur-
rent study, preoperative statin therapy was associated with
improved survival on univariate analysis in the entire cohort
but was not an independent predictor on Cox regression.
In addition, preoperative statin use was neither a predictor
of patency nor limb salvage in the entire population or in
the DM cohort. Further studies are necessary to examine
the specific dose effects of statins on peripheral endovascu-
lar intervention outcomes.
Exogenous insulin has known mitogenic effects, in-
cluding increased smooth muscle cell migration and prolif-eration.27 The exact role of insulin in the outcome of
percutaneous interventions is unclear because the mito-
genic effect of insulin may be outweighed by tighter glyce-
mic control.28,29 Intermediate results from our institution
found insulin-dependent DM (IDDM) was an indepen-
dent predictor of infrainguinal PTA failure.19 Bakken et al8
found that IDDM was associated with decreased AP rates
compared with non-DM in patients presenting with clau-
dication, but PP and limb salvage were equivalent. Further-
more, PP and AP rates were similar between IDDM and
non-DM patients in the critical limb ischemia group, but
limb salvage was decreased in IDDMpatients. These results
suggest that patients with IDDM have poor outcomes after
endovascular intervention under certain conditions; how-
ever, IDDM was not an independent predictor of any
outcome on Cox proportional hazards in the claudicant or
critical limb ischemia group. Similarly in the current study,
insulin use was not an independent predictor of any long-
term outcome in the entire cohort or in the DM group.
This would suggest that the benefits of tight glycemic
control outweigh themitogenic effects of insulin in diabetic
patients.
In the current series, there was no significant difference
in AP rates between the two groups. This has been the rule
in the literature: most studies have reported no difference in
AP due to DM.1,9,15,30,31 Bakken et al8 found a decrease in
AP of their claudicant cohort of superficial femoral artery
interventions, although there was no difference in AP of
their critical limb ischemia cohort. Similar AP between
diabetic and nondiabetic patients has often been attributed
to close surveillance and an aggressive approach to reinter-
vention, but may also be a consequence of the limited
follow-up after the second procedure. Ryer et al32 reviewed
the outcomes of failed PTA/stent and reported that rein-
tervention was more often necessary in diabetic patients but
that approximately 82% of primary failures could be sal-
vaged with endovascular means.
The results of limb salvage in diabetic patients under-
going infrainguinal endovascular interventions have been
inconsistent. Bakken et al8 reported a statistically significant
decrease in the limb salvage of diabetic patients compared
with nondiabetic patients with critical limb ischemia under-
going superficial femoral artery endovascular interventions.
This finding is consistent with the current study in which
DM predicted limb loss in the entire cohort. However,
when the critical limb ischemia cohort was considered
alone, DM was not a factor. This finding is supported by
DeRubertis et al,9 who showed no difference in limb sal-
vage between diabetic and nondiabetic patients with critical
limb ischemia undergoing any infrainguinal endovascular
intervention. Therefore, the difference in limb salvage in
our study was due to eventual limb loss in diabetic patients
initially treated for claudication who were more likely to
have femoropopliteal interventions in the setting of im-
paired runoff.
We previously reported that DM was a significant pre-
dictor of limb loss in patients undergoing femoropopliteal
PTA/stent with 2-year follow-up with all of the limb loss
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 2 Abularrage et al 321occurring in the critical limb ischemia cohort.1 This would
suggest that patients who underwent femoropopliteal in-
tervention alone for critical limb ischemia likely had com-
promised runoff that made them more vulnerable to limb
loss in the setting of patency failure.
To our knowledge, this is the first report of PTA/stent
outcomes to show decreased limb salvage in claudicant
patients. Indeed, many series have not included claudicant
patients in limb-salvage calculations because it was discour-
aged by the SVS reporting standards on lower extremity
outcomes, and within a limited follow-up period, these
patients would not be expected to progress to critical limb
ischemia.33 In this series, however, seven patients presented
with Rutherford 3 level claudication, were treated with
PTA/stent that failed, and their condition degenerated to
critical limb ischemia1 year of the initial procedure. With
additional endovascular and open revascularization, ampu-
tation was avoided for an average of 30 months. Bakken et
al8 reported that claudicant diabetic patients have a signif-
icantly inferior AP compared with nondiabetic patients, but
because of limited follow-up, this did not lead to decreased
limb salvage. This gradual progression to limb loss in the
face of poor assisted patency levels highlights the need for
long-term follow-up when assessing the efficacy of PTA/
stent in certain high risk populations.
Limitations of this study include its retrospective nature
and the potential for referral/selection bias given the single-
center experience. Furthermore, patency was determined
by return of symptoms and change in noninvasive studies.
Ideally, patency would be assessed with duplex ultrasound
imaging or angiography in a prospective manner, but this is
neither cost-effective nor necessary in the clinical setting.
CONCLUSIONS
The overall goal in lower extremity revascularization is
to preserve lower extremity blood flow and function, avoid
amputation, and decrease mortality.34 Previous studies
have shown that the morbidity and mortality associated
with lower extremity bypass remains significant despite
advances in the perioperative management of these pa-
tients.3 This morbidity and mortality is further exacerbated
in patients with preoperative underlying illness and poor
functional status.35,36 As shown in the current study, limb
salvage rates achieved with an aggressive endovascular ap-
proach can be comparable to those achieved with open
bypass.37 Thus, infrainguinal PTA/stent can be an effective
first-line therapy in the treatment of chronic lower extrem-
ity ischemia in diabetic patients, especially in the absence of
adequate vein conduit, and in patients with prohibitive
cardiovascular risk.
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aMean  standard error of the mean.
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Volume 52, Number 2 Abularrage et al 322.e1Appendix Table I (online only). Univariate analysis of
demographic, clinical, and anatomic variables for primary
patency in all patients
Variable Overall P value
Limbs, No. 1075
Preoperative comorbidities
Age, ya 71.15  0.34 .65
History of tobacco use 774 .24
Male gender 691 .59
Hypertension 996 .93
Congestive heart failure 185 .39
Coronary artery disease 661 .19
Diabetes mellitus 533 .009
Chronic renal insufficiency 278 .91
Dialysis 78 .002
Hypercholesterolemia 835 .85
Preoperative medications
Statin 768 .53
Indications
Claudication (Rutherford
class 1-3) 627 .0001
CLI (Rutherford class 4-6) 448 .0001
Runoff
Single-vessel 331 .005
Single-vessel peroneal 110 .0002
Lesion characteristics
Stenosis only 596 .24
Occlusion only 306 .16
Sum lesion lengths, cma 6.91  0.20 .25
Femoropopliteal TASC I
TASC IA 124 .58
TASC IB/C/D 655 .58
Femoropopliteal TASC II
TASC IIA 56 .73
TASC IIB/C/D 690 .73
Tibial TASC
Tibial TASC A 0 —
Tibial TASC B 0 —
Tibial TASC C 148 .81
Tibial TASC D 100 .81
Intervention
SFA/popliteal 919 .14
Isolated femoropopliteal 778 .03
Isolated tibial 89 .05
Multilevel 208 .28
Multivessel 516 .09
Stent 361 .05
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
InterSociety Consensus.
aMean  standard error of the mean.Appendix Table II (online only). Univariate analysis of
demographic, clinical, and anatomic variables for assisted
patency in all patients
Variable Overall P value
Limbs, No. 1075
Preoperative comorbidities
Age, ya 71.15  0.34 .13
History of tobacco use 774 .95
Male gender 691 .46
Hypertension 996 .28
Congestive heart failure 185 .41
Coronary artery disease 661 .49
Diabetes mellitus 533 .18
Chronic renal insufficiency 278 .57
Dialysis 78 .54
Hypercholesterolemia 835 .92
Preoperative medications
Statin 768 .35
Indications
Claudication (Rutherford
class 1-3) 627 .07
CLI (Rutherford class 4-6) 448 .07
Runoff
Single-vessel 331 .02
Single-vessel peroneal 110 .19
Lesion characteristics
Stenosis only 596 .31
Occlusion only 306 .53
Sum lesion lengths, cma 6.91  0.20 .53
Femoropopliteal TASC I
TASC IA 124 .36
TASC IB/C/D 655 .36
Femoropopliteal TASC II
TASC IIA 56 .03
TASC IIB/C/D 690 .03
Tibial TASC
Tibial TASC A 0 ...
Tibial TASC B 0 ...
Tibial TASC C 148 .63
Tibial TASC D 100 .63
Intervention
SFA/popliteal 919 .08
Isolated femoropopliteal 778 .26
Isolated tibial 89 .32
Multilevel 208 .54
Multivessel 516 .29
Stent 361 .98
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
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of demographic, clinical, and anatomic variables for limb
salvage in all patients
Variable Overall P value
Limbs, No. 1075
Preoperative comorbidities
Age, ya 71.15  0.34 .84
History of tobacco use 774 .004
Male gender 691 .43
Hypertension 996 .67
Congestive heart failure 185 .006
Coronary artery disease 661 .37
Diabetes mellitus 533 .0001
Chronic renal insufficiency 278 .04
Dialysis 78 .0001
Hypercholesterolemia 835 .05
Preoperative medications
Statin 768 .25
Indications
Claudication (Rutherford
class 1-3) 627 .0001
CLI (Rutherford class 4-6) 448 .0001
Runoff
Single-vessel 331 .0002
Single-vessel peroneal 110 .0001
Lesion characteristics
Stenosis only 596 .71
Occlusion only 306 .59
Sum lesion lengths, cma 6.91  0.20 .26
Femoropopliteal TASC I
TASC IA 124 .11
TASC IB/C/D 655 .11
Femoropopliteal TASC II
TASC IIA 56 .35
TASC IIB/C/D 690 .35
Tibial TASC
Tibial TASC A 0 —
Tibial TASC B 0 —
Tibial TASC C 148 .22
Tibial TASC D 100 .22
Intervention
SFA/popliteal 919 .0001
Isolated femoropopliteal 778 .01
Isolated tibial 89 .0001
Multilevel 208 .59
Multivessel 516 .53
Stent 361 .0006
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
InterSociety Consensus.
aMean  standard error of the mean.Appendix Table IV (online only). Univariate analysis
of demographic, clinical, and anatomic variables for
survival in all patients
Variable Overall P value
Patients, No. 920
Preoperative comorbidities
Age, ya 71.14  0.37 .0001
History of tobacco use 655 .12
Male gender 590 .54
Hypertension 848 .53
Congestive heart failure 152 .0001
Coronary artery disease 558 .002
Diabetes mellitus 459 .0001
Chronic renal insufficiency 241 .0001
Dialysis 65 .0001
Hypercholesterolemia 713 .0001
Preoperative medications
Statin 657 .004
Indications
Claudication (Rutherford
class 1-3) 530 .0001
CLI (Rutherford class 4-6) 390 .0001
Runoff
Single-vessel 277 .0009
Single-vessel peroneal 95 .0001
Lesion characteristics
Stenosis only 504 .08
Occlusion only 265 .94
Sum lesion lengths, cma 6.97  0.21 .79
Femoropopliteal TASC I
TASC IA 96 .55
TASC IB/C/D 562 .55
Femoropopliteal TASC II
TASC IIA 49 .03
TASC IIB/C/D 575 .03
Tibial TASC
Tibial TASC A 0 —
Tibial TASC B 0 —
Tibial TASC C 137 .42
Tibial TASC D 88 .42
Intervention
SFA/popliteal 775 .46
Isolated femoropopliteal 649 .0002
Isolated tibial 85 .33
Multilevel 186 .0004
Multivessel 457 .0001
Stent 304 .21
Amputation
Any amputation 137 .0001
Minor amputation 79 .0001
Major amputation 58 .0001
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
InterSociety Consensus.
aMean  standard error of the mean.
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demographic, clinical, and anatomic variables for primary
patency in diabetic patients
Variable Overall P value
Limbs, No. 533
Preoperative comorbidities
Age, ya 70.41  0.47 .33
History of tobacco use 377 .80
Male gender 368 .93
IDDM 255 .76
NIDDM 278 .76
Hypertension 504 .67
Congestive heart failure 114 .25
Coronary artery disease 368 .03
Chronic renal insufficiency 175 .69
Dialysis 56 .26
Hypercholesterolemia 427 .65
Preoperative medications
Statin 391 .22
Indications
Claudication (Rutherford
class 1-3) 245 .002
CLI (Rutherford class 4-6) 288 .002
Runoff
Single-vessel 205 .51
Single-vessel peroneal 78 .04
Lesion characteristics
Stenosis only 292 .24
Occlusion only 145 .16
Sum lesion lengths, cma 6.87  0.26 .48
Femoropopliteal TASC I
TASC IA 57 .75
TASC IB/C/D 311 .75
Femoropopliteal TASC II
TASC IIA 30 .93
TASC IIB/C/D 325 .93
Tibial TASC
Tibial TASC A 0 —
Tibial TASC B 0 —
Tibial TASC C 95 .19
Tibial TASC D 59 .19
Intervention
SFA/popliteal 445 .51
Isolated femoropopliteal 350 .73
Isolated tibial 58 .34
Multilevel 125 .75
Multivessel 271 .66
Stent 160 .18
CLI, Critical limb ischemia; IDDM, insulin-dependent diabetes mellitus;
NIDDM, non-insulin-dependent diabetes mellitus; SFA, superficial femoral
artery; TASC, TransAtlantic InterSociety Consensus.
aMean  standard error of the mean.Appendix Table VI (online only). Univariate analysis
of demographic, clinical, and anatomic variables for
assisted patency in diabetic patients
Variable Overall P value
Limbs, No. 533
Preoperative comorbidities
Age, ya 70.41  0.47 .04
History of tobacco use 377 .79
Male gender 368 .49
IDDM 255 .56
NIDDM 278 .56
Hypertension 504 .47
Congestive heart failure 114 .58
Coronary artery disease 368 .93
Chronic renal insufficiency 175 .81
Dialysis 56 .17
Hypercholesterolemia 427 .87
Preoperative medications
Statin 391 .03
Indications
Claudication (Rutherford
class 1-3) 245 .14
CLI (Rutherford class 4-6) 288 .14
Runoff
Single-vessel 205 .77
Single-vessel peroneal 78 .19
Lesion characteristics
Stenosis only 292 .64
Occlusion only 145 .95
Sum lesion lengths, cma 6.87  0.26 .92
Femoropopliteal TASC I
TASC IA 57 .69
TASC IB/C/D 311 .69
Femoropopliteal TASC II
TASC IIA 30 .05
TASC IIB/C/D 325 .05
Tibial TASC
Tibial TASC A 0 ...
Tibial TASC B 0 ...
Tibial TASC C 95 .47
Tibial TASC D 59 .47
Intervention
SFA/popliteal 445 .07
Isolated femoropopliteal 350 .99
Isolated tibial 58 .16
Multilevel 125 .32
Multivessel 271 .83
Stent 160 .89
CLI, Critical limb ischemia; IDDM, insulin-dependent diabetes mellitus;
NIDDM, non-insulin-dependent diabetes mellitus; SFA, superficial femoral
artery; TASC, TransAtlantic InterSociety Consensus.
aMean  standard error of the mean.
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of demographic, clinical, and anatomic variables for limb
salvage in diabetic patients
Variable Overall P value
Limbs, No. 533
Preoperative comorbidities
Age, ya 70.41  0.47 .79
History of tobacco use 377 .05
Male gender 368 .68
IDDM 255 .44
NIDDM 278 .44
Hypertension 504 .72
Congestive heart failure 114 .06
Coronary artery disease 368 .96
Chronic renal insufficiency 175 .44
Dialysis 56 .01
Hypercholesterolemia 427 .03
Preoperative medications
Statin 391 .18
Indications
Claudication (Rutherford
class 1-3) 245 .0001
CLI (Rutherford class 4-6) 288 .0001
Runoff
Single-vessel 205 .01
Single-vessel peroneal 78 .14
Lesion characteristics
Stenosis only 292 .93
Occlusion only 145 .80
Sum lesion lengths, cma 6.87  0.26 .29
Femoropopliteal TASC I
TASC IA 57 .12
TASC IB/C/D 311 .12
Femoropopliteal TASC II
TASC IIA 30 .57
TASC IIB/C/D 325 .57
Tibial TASC
Tibial TASC A 0 —
Tibial TASC B 0 —
Tibial TASC C 95 .31
Tibial TASC D 59 .31
Intervention
SFA/popliteal 445 .07
Isolated femoropopliteal 350 .83
Isolated tibial 58 .08
Multilevel 125 .13
Multivessel 271 .83
Stent 160 .05
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
InterSociety Consensus.
aMean  standard error of the mean.Appendix Table VIII (online only). Univariate analysis
of demographic, clinical, and anatomic variables for
survival in diabetic patients
Variable Overall P value
Patients, No. 459
Preoperative comorbidities
Age, ya 70.35  0.51 .0001
History of tobacco use 317 .70
Male gender 315 .80
IDDM 225 .008
NIDDM 234 .008
Hypertension 431 .91
Congestive heart failure 99 .0001
Coronary artery disease 313 .07
Chronic renal insufficiency 154 .0001
Dialysis 49 .0001
Hypercholesterolemia 367 .02
Preoperative medications
Statin 337 .36
Indications
Claudication (Rutherford
class 1-3) 208 .0001
CLI (Rutherford class 4-6) 246 .0001
Runoff
Single-vessel 172 .32
Single-vessel peroneal 65 .14
Lesion characteristics
Stenosis only 248 .11
Occlusion only 126 .93
Sum lesion lengths, cma 6.93  0.28 .77
Femoropopliteal TASC I
TASC IA 46 .47
TASC IB/C/D 264 .47
Femoropopliteal TASC II
TASC IIA 27 .02
TASC IIB/C/D 274 .02
Tibial TASC
Tibial TASC A 0 ...
Tibial TASC B 0 ...
Tibial TASC C 88 .20
Tibial TASC D 52 .30
Intervention
SFA/popliteal 378 .83
Isolated femoropopliteal 292 .02
Isolated tibial 56 .84
Multilevel 111 .01
Multivessel 243 .02
Stent 136 .31
Amputation
Any amputation 103 .0001
Minor amputation 59 .0002
Major amputation 44 .03
CLI, Critical limb ischemia; SFA, superficial femoral artery; TASC, TransAtlantic
InterSociety Consensus.
aMean  standard error of the mean.
